With more than 35 years at the forefront of fertility care, Herts & Essex Fertility Centre has helped bring over 8,000 babies into the world and supported thousands of families in achieving their dream of parenthood. Delivering more than 1,000 cycles each year, the centre is widely recognised for its high-quality, personalised approach to care. Every treatment plan is carefully tailored to the individual needs of each patient, ensuring compassionate support alongside clinical excellence. The acquisition brings together two organisations united by a shared commitment to clinical excellence, compassionate care and patient-centred treatment. Together, FutureLife and Herts & Essex Fertility Centre will continue to focus on advancing fertility care while maintaining the highest standards of medical and ethical practice. FutureLife now offers patients world class medical care and patient experience across the south of the UK with Bristol Centre for Reproductive Medicine (BCRM) based in the southwest, The Centre for Reproductive and Genetic Health (CRGH) based in central London (CRGH) and now the southeast with the addition of Herts & Essex Fertility Centre. Francisco Lobbosco, CEO of FutureLife, commented: “We are delighted to welcome Herts & Essex Fertility Centre to the FutureLife family. This acquisition reflects our shared belief that fertility care should be clinically excellent, ethically delivered and deeply personal. Herts & Essex has an outstanding reputation, and we are proud to support its team as they continue their important work.” Michael Ah-Moye, Founder of Herts & Essex Fertility Centre, commented: “Joining the FutureLife Group allows us to build on our strong foundations while preserving the values, culture and quality of care our patients trust. Our focus remains unchanged: delivering the highest standard of fertility treatment, tailored to each individual.” Grant Thornton and Gardner Leader acted as advisers to the shareholders of Herts & Essex. About FutureLife  FutureLife is one of the leading European providers of IVF, fertility treatments and related genetic services. With 60+ well-invested clinics, in 16 countries, employing more than 2,100 specialists performing in excess of 77,000 IVF cycles annually, as well as a series of gynaecological and surgical treatments. In addition to its fertility clinic portfolio, FutureLife also operates two hospitals in the Czech Republic and the GNT Lab, one of the largest and most modern genetic laboratories in Europe and enables the group to meet the demand for genetic services with speed and efficiency, raising the level of care provided to the group’s patients. The team at FutureLife believe in a world where everyone has the freedom to create a family and adopt an evidence-based approach to the innovation of treatment strategies, with a mission statement focused on ethics and standards. FutureLife is co-owned by funds under the management of CVC and Hartenberg. www.futurelifegroup.com Press contacts  For FutureLife: pressoffice@futurelifegroup.com